Intraarterial route increases the risk of cerebral lesions after mesenchymal cell administration in animal model of ischemia

Citations Over TimeTop 10% of 2017 papers

Abstract

Mesenchymal stem cells (MSCs) are a promising clinical therapy for ischemic stroke. However, critical parameters, such as the most effective administration route, remain unclear. Intravenous (i.v.) and intraarterial (i.a.) delivery routes have yielded varied outcomes across studies, potentially due to the unknown MSCs distribution. We investigated whether MSCs reached the brain following i.a. or i.v. administration after transient cerebral ischemia in rats, and evaluated the therapeutic effects of both routes. MSCs were labeled with dextran-coated superparamagnetic nanoparticles for magnetic resonance imaging (MRI) cell tracking, transmission electron microscopy and immunohistological analysis. MSCs were found in the brain following i.a. but not i.v. administration. However, the i.a. route increased the risk of cerebral lesions and did not improve functional recovery. The i.v. delivery is safe but MCS do not reach the brain tissue, implying that treatment benefits observed for this route are not attributable to brain MCS engrafting after stroke.

Related Papers

• → Evaluation of Brain Ischemia in Mice(2005)17 cited
• → Towards a dynamical network view of brain ischemia and reperfusion. Part I: background and preliminaries(2010)2 cited
• Platelet-activating factor in brain after regional ischemia in gerbils and rats(1999)
• EFFECT OF β-AESCINATE ON NO METABOLISM IN BRAIN ISCHEMIA AND ISCHEMIA-REPERFUSION MODEL OF RATS(2003)
• → Changes In the Course of Energy and Oxidative Processes of The Brain During Its Ischemia(2023)